Bio-Reference Laboratories, Inc. (NASDAQ:BRLI)

Mod CAP

Bad marketing & commercial practices giving less good financial results !

low peg

consensus screen

Alas....

Bought the stock around $14 wish I found out about it earlier. Strong earnings in a weak economy, great growth stock.

I wish I entered this yesterday...very high growth, over 20% ROE. It's a growth stock, but its P/E is 2/3 of LabCorp's and only about half of Quest Diagnostics. The reason why it's so low is because some short-selling site alleged shady business practices, shorted the stock, then covered its position within the next few days (apparently constant double digit growth for a $400M market cap company in a giant and rapidly expanding industry is cause for alarm). Short % of float is almost 30%, and they just posted record profits. This opportunity won't last long.

HG

Low PEG for 20% Growth

SC QC Limit 21.21

Favorable demographics, smaller company than industry's largest with better growth or acquisition prospects.

I work in Healthcare, this lab has just come into our organization, we currently use labcorp and quest. I started researching bio-referance and it seems a strong company. lots of positives (growth, gendx, cancer research etc). still researching but may grab some today.

gene testing and other niche tests coming into demand

22.97

New Jersey-based healthcare small-cap providing clinical laboratory testing services for regional healthcare providers. Should continue profiting from our aging population and industry changes resulting from the new health care bill.

stock split, and healthcare

People are always having tests done so a company like this is a cash cow. It could be a takeover candidate for Quest or maybe Mr. Buffet may feel warm blooded and buy this body fluid testing company.

This pick based solely on passage of the healthcare bill. Bill passes, millions of new tests will be ordered and this company will most likely prosper; no healthcare bill, business as usual and this company will still do just fine. (Based on the performance and numbers I've seen to date...)

Small cap stock with too good to be true earning performance, maybe that's a warning sign?. While sales and earnings haven't been deterred by this economic downturn, the P/E ratio has been reduced from about 30 to about 20. Expect this company to keep growing at 20%, perhaps P/E will creep back up again, maybe they'll get bought out by a bigger player.